Sukumar Nagendran Sells 1,780 Shares of AveXis, Inc. (AVXS) Stock
AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $97.25, for a total value of $173,105.00. Following the transaction, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $173,105. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Sukumar Nagendran also recently made the following trade(s):
- On Friday, September 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $93.25, for a total value of $165,985.00.
- On Tuesday, August 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $91.52, for a total value of $162,905.60.
Shares of AveXis, Inc. (NASDAQ AVXS) traded up 3.67% during mid-day trading on Tuesday, reaching $99.27. The company’s stock had a trading volume of 623,475 shares. The firm’s market capitalization is $3.17 billion. The company’s 50-day moving average is $93.36 and its 200 day moving average is $82.25. AveXis, Inc. has a 1-year low of $41.89 and a 1-year high of $102.00.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same quarter last year, the business posted ($0.68) EPS. On average, analysts expect that AveXis, Inc. will post ($6.04) earnings per share for the current year.
AVXS has been the topic of a number of research analyst reports. UBS AG reaffirmed a “buy” rating and issued a $122.00 price target (up from $95.00) on shares of AveXis in a research note on Tuesday. Citigroup Inc. boosted their price target on AveXis from $100.00 to $116.00 and gave the stock a “buy” rating in a research report on Monday. BMO Capital Markets reissued an “outperform” rating and issued a $123.00 price objective on shares of AveXis in a research note on Saturday. Wells Fargo & Company reissued an “outperform” rating on shares of AveXis in a research note on Friday. Finally, Royal Bank Of Canada initiated coverage on AveXis in a report on Thursday, September 14th. They issued a “sector perform” rating and a $92.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company’s stock. AveXis currently has a consensus rating of “Buy” and a consensus price target of $101.82.
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in AveXis by 3,055.6% during the 1st quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after buying an additional 1,654,248 shares during the last quarter. Janus Henderson Group PLC purchased a new position in AveXis during the second quarter worth $55,439,000. Alliancebernstein L.P. increased its position in AveXis by 4,448.8% during the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock worth $46,418,000 after buying an additional 552,546 shares in the last quarter. FMR LLC increased its position in AveXis by 13.1% during the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock worth $386,598,000 after buying an additional 544,475 shares in the last quarter. Finally, State Street Corp increased its position in AveXis by 104.2% during the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock worth $82,163,000 after buying an additional 510,189 shares in the last quarter. 94.71% of the stock is currently owned by hedge funds and other institutional investors.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.